drugset / Trial / NCT00088556
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Timeline
- Start
- 2004-08
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Subject | canfosfamide | Small molecule | 400 mg/m2 | — |